GlassScriptPhysician profile
Jeffrey Wong
NPI 1134338429
$7,306.84
in general payments reported to CMS, 2019-2025
33 companies · $2,229 in 2025
The $2,229 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,220 · 2020: $415 · 2021: $292 · 2022: $1,083 · 2023: $993 · 2024: $1,074 · 2025: $2,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,458 · Long Term Medical Supply Or Device Loan: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,457.74 |
| Long Term Medical Supply Or Device Loan | $838.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,262.39 | 2019-2025 | Unity, Hydrus Microstent, Argos |
| Johnson & Johnson Surgical Vision, INC. | $600.77 | 2019-2024 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Amgen INC. | $509.50 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $387.92 | 2022-2025 | Envista Mx60 Iol, Envista Aspire Iol, Vyzulta |
| Sun Pharmaceutical Industries INC. | $367.15 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $318.80 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $266.56 | 2019 | |
| Sight Sciences, INC. | $231.44 | 2019-2024 | Omni Surgical System |
| Rxsight INC | $229.29 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $211.32 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $210.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $202.20 | 2019-2023 | |
| Oyster Point Pharma, INC. | $191.73 | 2022-2024 | Tyrvaya, Ryzumvi |
| Horizon Therapeutics Plc | $178.43 | 2022-2023 | Tepezza |
| Genentech USA, INC. | $141.50 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $132.28 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Dompe US, INC. | $125.00 | 2022 | |
| Apellis Pharmaceuticals, INC. | $112.48 | 2024 | Syfovre |
| Allergan, INC. | $99.02 | 2019-2022 | |
| Haag-Streit USA, INC. | $81.19 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $80.71 | 2020-2022 | |
| Harrow Eye, LLC | $47.49 | 2023-2025 | Iheezo, Verkazia, Flarex |
| Shire North American Group INC | $43.11 | 2019 | |
| New World Medical,INC. | $41.18 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $38.22 | 2024 | Acthar |
| Carl Zeiss Meditec USA, INC. | $37.86 | 2024 | |
| Eyevance Pharmaceuticals LLC | $35.06 | 2019-2020 | |
| Biotissue Holdings INC. | $25.00 | 2025 | |
| Kala Pharmaceuticals, INC. | $21.04 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $20.20 | 2023 | Zilretta, Iovera, Exparel |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Heidelberg Engineering, INC. | $19.18 | 2025 | Spectralis |
| Mallinckrodt Enterprises LLC | $18.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.